Jump to ContentJump to Main Navigation

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Editorial Board Member: Gillery, Philippe / Kazmierczak, Steven / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Schlattmann, Peter / Whitfield, John B.

12 Issues per year

40% increased IMPACT FACTOR 2012: 3.009
Rank 5 out of 31 in category Medical Laboratory Technology in the 2012 Thomson Reuters Journal Citation Report/Science Edition

VolumeIssuePage

Issues

Soluble urokinase plasminogen activator receptor (suPAR) levels in healthy pregnancy and preeclampsia

Gergely Toldi1, 2 / Edina Bíró3 / Balázs Szalay1, 2 / Balázs Stenczer4 / Attila Molvarec4 / János Rigó Jr4 / Barna Vásárhelyi2, 3 / Gabriella Bekõ3

1First Department of Pediatrics, Semmelweis University, Budapest, Hungary

2Research Group of Pediatrics and Nephrology, Hungarian Academy of Sciences, Budapest, Hungary

3Department of Laboratory Medicine, Semmelweis University, Budapest, Hungary

4First Department of Obstetrics and Gynecology, Semmelweis University, Budapest, Hungary

Corresponding author: Gergely Toldi, First Department of Pediatrics, Semmelweis University, Budapest, Bókay u. 53-54, 1083, Hungary Phone: +36-20-4367181, Fax: +36-1-3138212,

Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 49, Issue 11, Pages 1873–1876, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: 10.1515/cclm.2011.656, July 2011

Publication History:
Received:
2011-04-29
Accepted:
2011-05-23
Published Online:
2011-07-04

Abstract

Background: Preeclampsia is characterized by a maternal systemic inflammatory response and the impairment of maternal immune tolerance present in healthy pregnancy. Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker increasingly used for the monitoring of systemic inflammation. We aimed to assess the levels of suPAR and other markers of systemic inflammation in preeclampsia compared to healthy pregnancy.

Methods: We determined plasma suPAR, IL-6 and high sensitivity C-reactive protein (hs-CRP) levels in plasma samples of 62 healthy pregnant and 41 preeclamptic women in the third trimester of pregnancy.

Results: Plasma suPAR levels were elevated in preeclampsia [3.18 (2.30–4.71) ng/mL vs. 2.02 (1.81–2.40) ng/mL, p=0.0001, median (interquartile range)]. IL-6 and hs-CRP levels were also higher compared with healthy pregnancy [5.99 (2.97–18.12) pg/mL vs. 1.41 (1.00–2.70) pg/mL, p=0.0001 and 6.60 (3.55–15.40) mg/L vs. 3.90 (2.10–7.25) mg/L, p=0.006, respectively, median (interquartile range)]. Linear regression analyses revealed an association between individual plasma suPAR and log IL-6 levels as well as log hs-CRP levels.

Conclusions: suPAR levels are elevated in preeclampsia and vary in a narrower range compared with IL-6 and hs-CRP. ROC analysis indicated that monitoring of suPAR levels is a suitable tool for the detection of systemic inflammation in pregnancy.

Keywords: high sensitivity C-reactive protein; IL-6; preeclampsia; pregnancy; suPAR

Comments (0)

Please log in or register to comment.
Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.